PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6400420

Vascularized bone transfers.

A J Weiland
View original source ↗Export metadata ↓

Abstract

Our experience with microvascular transfer of autogenous fibular grafts and osteocutaneous groin flaps has been favorable. These technically demanding operative procedures have been employed in patients with severely traumatized extremities and those individuals with locally aggressive or low-grade malignant bone tumors who were not considered candidates for traditional methods of bone grafting. In many patients amputation would have been the only alternative. The treatment of congenital pseudarthrosis of the tibia remains one of the most challenging problems confronting the orthopaedic surgeon today. Although various techniques of bone grafting have been advocated in addition to the use of pulsating electromagnetic coils, a significant number of failures have occurred. Early experience with the technique of free vascularized fibular transfer in the treatment of these patients has been encouraging. A significant problem associated with free vascularized fibular grafts concerns the immediate postoperative monitoring of circulation to the graft. Unlike osteocutaneous groin flaps, in which the skin serves as a model for arterial inflow and venous outflow, the fibular graft is subcutaneous and not visible for direct monitoring. Bone scans have been used in the postoperative period (24 to 72 hours) and affords the surgeon reasonable assurance that circulation of the graft is intact. However, if circulation is not intact, a revision of anastomoses at this stage is not feasible. More effective methods of monitoring patency of anastomoses need to be developed. Thermocouples and laser Doppler flowmeters are being experimented with in several institutions. Microsurgery is not a discipline but rather a technique. It is a tool that can be used by any well-trained orthopaedic surgeon. With more experience clinically and in the laboratory the applicability of vascularized autogenous bone grafts in the treatment of musculoskeletal defects will become more clearly defined.

Explore related subjects

Bone NeoplasmsBone TransplantationBone and BonesChildChild, PreschoolFemaleFibulaGroinHumansMalePreoperative CarePseudarthrosisSurgical FlapsTibiaCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A J Weiland. 1984. Vascularized bone transfers.. https://pubmed.ncbi.nlm.nih.gov/6400420/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

Bone extracellular matrix stimulates invasiveness of estrogen-responsive human mammary MCF-7 cells.

Bone is the most frequent site of metastasis in breast cancer. This causes destructive osteolytic lesions. To achieve metastasis to bone, breast cancer cells must proliferate in a new microenvironment, arrest on extracellular matrix and invade. Breast cancer cells progress in the invasive processes only if they destroy bone with the assistance of osteoclasts. In this work, we present data suggesting that MCF-7 cells, an estradiol receptor-positive cell line that exhibits modest invasive capacity, proliferate in the presence of soluble factors secreted by the osteogenic cell line SaOS-2. The cells acquire a more aggressive phenotype when cultured on an extracellular matrix produced by the same osseous cell line. Acquisition of the invasive phenotype appears to be related to the capacity of bone extracellular matrix to induce the expression of urokinase-like plasminogen activator by MCF-7 cells, which is specific for MCF-7 cells, given that MDA-231 cells, an estradiol receptor-negative and more aggressive cell line, did not show significant changes when cultured in the presence of soluble and insoluble bone factors.

Bone Neoplasms↗
PubMed1999

External beam radiotherapy for painful osseous metastases: pooled data dose response analysis.

PURPOSE: Although the effectiveness of external beam irradiation in palliation of pain from osseous metastases is well established, the optimal fractionation schedule has not been determined. Clinical studies to date have failed to demonstrate an advantage for higher doses. To further address this issue, we conducted a pooled dose response analysis using data from published Phase III clinical trials. METHODS AND MATERIALS: Complete response (CR) was used as an endpoint because it was felt to be least susceptible to inconsistencies in assessment.The biological effective dose (BED) was calculated for each schedule using the linear-quadratic model and an alpha/beta of 10. Using SAS version 6.12, the data were fitted using a weighted linear regression, a logistic model, and the spline technique. Finally, BED was categorized, and odds ratios for each level were calculated. RESULTS: CR was assessed early and late in 383 and 1,007 patients, respectively. Linear regression on the early-response data yielded a poor fit and a nonsignificant dose coefficient. With the late-response data, there was an excellent fit (R-square = 0.842) and a highly significant dose coefficient (p = 0.0002). Fitting early CR to a logistic model, we could not establish a significant dose response relationship. However, with the late-response data there was an excellent fit and the dose coefficient was significantly different from zero (0.017 +/- 0.00524; p = 0.0012). Application of the spline technique or removal of an outlier resulted in an improved fit (p = 0.048 and p = 0.0001, respectively). Using BED of < 14.4 Gy as a reference level, the odds ratios for late CR were 2.29-3.32 (BED of 19.5-51.4 Gy, respectively). CONCLUSION: Our results demonstrate a clear dose-response for pain relief. Further testing of high intensity regiments is warranted.

Bone Neoplasms↗
PubMed1999

S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme.

The biological function of the metastasis-associated gene S100A4 is not fully understood, although there is evidence indicating interactions between the gene product and the cytoskeleton. We have examined whether an association could exist between S100A4 and the regulation of matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs). For these studies, three clones of a highly metastatic human osteosarcoma cell line (OHS) transfected with a hammerhead ribozyme directed against the S100A4 gene transcript were used. The clones demonstrated different expression levels of S100A4 and also different metastatic capacity. In the clone with the most prominent down-regulation of S100A4, the mRNA levels of MMP2, membrane type (MT) 1-MMP, and TIMP-1 were significantly reduced in exponentially growing cultures. Western blots, gelatin zymography, and ELISA showed similar expression patterns of MMPs and TIMPs at the protein level. In the clones with an intermediate expression of S100A4, reduced expression of MT1-MMP and TIMP-1 was detected, whereas the expression of MMP-2 was at the same level as in the control cells. In contrast to the other factors, TIMP-2 was up-regulated in all of the clones independent of the extent of ribozyme-induced down-regulation of S100A4. The transwell chamber assay demonstrated that the capacity of the ribozyme-transfected cells to cross uncoated filters was reduced, relative to control cells, according to the reduction in the S100A4 expression level. The clone with the lowest reduction in S100A4 did not demonstrate different motility compared with control cells, whereas transfectants with only 5% S100A4 mRNA showed a 50% reduction in motility. Interestingly, this trend was even more striking when the capacity to cross Matrigel-coated filters was analyzed, as all the clones demonstrated between 40 and 75% reduced invasion. It is concluded that S100A4 may exert its effect on metastasis formation not only by stimulating the motility of tumor cells but also by affecting their invasive properties through influencing the expression of MMPs and their endogenous inhibitors.

Bone Neoplasms↗